XOMA Ltd. has received a $1 million milestone payment from Takeda Pharmaceutical Co. Ltd. for achieving a preclinical milestone under the companies’ 2006 collaboration agreement. Under the collaboration, XOMA is using its collection of antibody discovery, development and optimization technologies to discover therapeutic antibodies against multiple targets selected by Takeda.

“Our successful collaboration with Takeda is producing promising antibody development candidates,” said Steven Engle, XOMA’s chairman and chief executive officer. “This and our other antibody discovery, development and licensing collaborations are important revenue sources for XOMA.”